Evidence map›Paper›PMID 28448774›Full record

ArticleJournal of managed care & specialty pharmacy2017

Letter--The Authors Respond.

Kibum Kim, Robert J DiDomenico, Daniel R Touchette, Surrey M Walton

Abstract readCommentLetter
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Kibum Kim1 Pharmacotherapy Outcomes Research Center Department of Pathology University of Utah.
Robert J DiDomenico2 Center for Pharmacoepidemiology and Pharmacoeconomic Research Department of Pharmacy Practice, College of Pharmacy University of Illinois at Chicago.
Daniel R Touchette3 Center for Pharmacoepidemiology and Pharmacoeconomic Research Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago.
Surrey M Walton4 Center for Pharmacoepidemiology and Pharmacoeconomic Research Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

disclosuresNone of the authors of this study are involved in financial or personal relationships with agencies, institutions, or organizations that inappropriately influenced the statistical analysis plan or interpretation of the study results. DiDomenico received an honorarium from Amgen for the preparation of a heart failure drug monograph for Pharmacy Practice News and was a coinvestigator on funded research for the Patient-Centered Outcomes Research Institute. DiDomenico also serves as an advisory board member for a heart failure program at Otsuka America Pharmaceuticals and as an advisory board member at Novartis Pharmaceuticals. Touchette has received unrestricted grant funding from Cardinal Health and Sunovion Pharmaceuticals and has also served as a consultant to, and director of, the American College of Clinical Pharmacy Practice-Based Research Network on a study funded by Pfizer.

Indexed as

Acute Coronary SyndromePercutaneous Coronary InterventionPharmaceutical ServicesHumansPatient Outcome AssessmentPurinergic P2Y Receptor AntagonistsUnited StatesPurinergic P2Y Receptor Antagonists

Identifiers

PMID28448774
PMCPMC10398221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.